All In Biotech

NDA 021883 · Abbvie

Dalvance

Dalbavancin Hydrochloride · Intravenous

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Jan 13, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

May 23, 2014

Approved uses

3

Original approval plus efficacy supplements

Registered trials

28

9 Phase 3, 3 recruiting

FAERS reports

1,005

456 serious, 21 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 13, 2025.

1 INDICATION AND USAGE DALVANCE is a lipoglycopeptide antibacterial indicated for the treatment of adult and pediatric patients with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of Gram-positive microorganisms. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of DALVANCE and other antibacterial drugs, DALVANCE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.2 ) 1.1 Acute Bacterial Skin and Skin Structure Infections DALVANCE ® is indicated for the treatment of adult and pediatric patients with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant isolates), Streptococcus pyogenes , Streptococcus agalactiae , Streptococcus dysgalactiae , Streptococcus anginosus group (including S. anginosus , S. intermedius , S . constellatus ) and Enterococcus faecalis (vancomycin susceptible isolates). 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of DALVANCE and other antibacterial agents, DALVANCE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Mechanism: Dalbavancin is an antibacterial drug [see Microbiology ( 12.4 )] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 22, 2021 Supplement 10 · Efficacy LabelLetter
  • Jan 20, 2016 Supplement 3 · Efficacy · priority review ReviewLabelLetter
  • May 23, 2014 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
1 products under this application
  • DALVANCE · DALBAVANCIN HYDROCHLORIDE EQ 500MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Dalbavancin" as an intervention, any sponsor and status, largest first.

All 28 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use148
  • rash96
  • back pain59
  • pruritus59
  • drug ineffective58
  • nausea57
  • dyspnoea54
  • vomiting51
  • hypersensitivity46
  • erythema42
  • urticaria39
  • pyrexia35

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201413
201518
201647
201778
201852
201975
2020100
202182
202294
202380
2024145
2025127
202694

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Dalvance (Dalbavancin HCl)

2024 spending

$17.9M

Beneficiaries

1,693

3,699 claims

Per beneficiary

$10,553

$663.48 per unit

View as table
YearSpending
2020$6,073,007
2021$7,892,769
2022$10,515,065
2023$13,677,432
2024$17,866,532

Part B: Dalvance (Dalbavancin HCL) · HCPCS J0875

2024 spending

$59.5M

Beneficiaries

7,974

15,829 claims

Per beneficiary

$7,460

2024 ASP limit $15.45 per unit

View as table
YearSpending
2020$34,199,278
2021$44,071,351
2022$47,053,003
2023$54,207,841
2024$59,483,378

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 48 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.